ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Update

ENDRA Life Sciences Inc. (NASDAQ:NDRA) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 42,119 shares, a growth of 92.3% from the June 15th total of 21,904 shares. Currently, 3.7% of the company’s shares are short sold. Based on an average daily volume of 81,330 shares, the short-interest ratio is presently 0.5 days.

Institutional Trading of ENDRA Life Sciences

An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC purchased a new stake in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences accounts for about 0.9% of Altium Capital Management LLC’s holdings, making the stock its 17th largest position. Altium Capital Management LLC owned approximately 6.92% of ENDRA Life Sciences as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 1.19% of the company’s stock.

Analyst Upgrades and Downgrades

NDRA has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of ENDRA Life Sciences in a research report on Monday, April 20th. Ascendiant Capital Markets cut their price objective on ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, June 1st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $25.00.

ENDRA Life Sciences Stock Performance

Shares of NASDAQ:NDRA traded down $0.34 during mid-day trading on Thursday, hitting $5.27. The stock had a trading volume of 26,750 shares, compared to its average volume of 67,506. The company’s 50 day moving average is $5.11 and its 200-day moving average is $4.58. ENDRA Life Sciences has a 12-month low of $2.96 and a 12-month high of $9.85. The company has a market cap of $6.69 million, a PE ratio of -0.65 and a beta of -0.06.

ENDRA Life Sciences (NASDAQ:NDRA) last posted its quarterly earnings data on Friday, May 15th. The company reported ($1.09) earnings per share for the quarter, topping the consensus estimate of ($1.23) by $0.14. On average, equities research analysts predict that ENDRA Life Sciences will post -4.11 EPS for the current fiscal year.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.